Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reflects strong financial performance with record revenue and profitability, particularly in the Life Sciences and M&A sectors. Although there are increased costs and a restructuring charge, the company maintains a positive outlook with strong demand and utilization rates. The Q&A reveals optimism about talent acquisition and growth despite some general responses. Given the market cap, this translates to a positive stock price movement, likely between 2% to 8%.
Revenue $201 million, a 10.5% increase year-over-year. This represents the highest quarterly revenue in the company's history, driven by broad-based contributions with 8 practices growing year-over-year. Specific practices like Energy, Finance, Forensic Services, and Life Sciences posted double-digit revenue growth.
North American Operations Revenue Increased by 8.5% year-over-year, driven by broad-based contributions.
International Operations Revenue Expanded by 20.3% year-over-year, reflecting strong performance across geographies.
Consultant Headcount Increased by 2.5% year-over-year to 971, supported by replenishing of the sales pipeline and increased project originations.
Consultant Utilization Improved to 77% year-over-year, supported by increased project lead flow and new project originations.
Non-GAAP EBITDA $23.2 million, representing 11.5% of revenue. This was affected by higher employee-related benefit costs and taxes due to annual bonuses. Noncash amortization of forgivable loans increased by $4.8 million or 53% year-over-year.
Legal and Regulatory Services Revenue Increased by 11.5% year-over-year, in line with broader legal market growth.
Worldwide M&A Activity Totaled $1.2 trillion, a 27% increase year-over-year, marking the strongest opening quarter for dealmaking since 2021.
Restructuring Charge $2.6 million, affecting 22 individuals across various practices and departments. This includes $1.6 million in cash charges and $1.0 million in noncash charges, with anticipated annual cost savings of approximately $5 million.
Capital Deployment Net cash outlays of $62.3 million for talent investments, including senior talent acquisition, performance awards, and talent retention. $25.3 million returned to shareholders through dividends and share repurchases.
Cash and Borrowings $32.5 million in cash and $192 million in borrowings under the revolving credit facility, resulting in net debt of $159.5 million. Borrowings were elevated to fund annual bonus payments.
Liquidity $86.7 million, consisting of $32.5 million in cash and $54.2 million of available capacity on the line of credit.
Credit Facility Increased by $50 million to $300 million of aggregate borrowing capacity to support growth and working capital needs.
Antitrust & Competition Economics practice: Delivered a record quarter, capitalizing on ongoing merger-related activity and continued demand for antitrust services. Supported major mergers and defended against damages claims in high-profile cases.
Energy practice: Supported a wide array of clients, including utilities, electric system operators, and private equity. Advised on data center tariffs, load management, and regulatory due diligence for solar portfolios.
Life Sciences practice: Developed strategies for pharmaceutical companies, including pricing and market access for new therapies. Conducted global pricing studies for combination therapies in cardiovascular and nephrology markets.
Geographic expansion: North American operations increased revenue by 8.5%, while international operations expanded by 20.3% year-over-year.
M&A market: Worldwide M&A activity totaled $1.2 trillion in Q1 2026, up 27% year-over-year. CRA's Antitrust & Competition Economics practice capitalized on this growth.
Consultant headcount and utilization: Consultant headcount increased by 2.5% year-over-year, and utilization improved to 77%.
Restructuring efforts: Reconfigured consulting teams, affecting 22 individuals, resulting in a $2.6 million restructuring charge but anticipated annual cost savings of $5 million.
AI integration: Positioned AI as a demand amplifier and productivity enhancer, emphasizing its role in enhancing CRA's expertise and credibility.
Capital deployment: Invested $62.3 million in talent acquisition and retention, and expanded credit facility by $50 million to support growth.
Economic and Geopolitical Conditions: The company acknowledges that evolving geopolitical, global macroeconomic, and business conditions could impact its operations and financial performance.
Restructuring and Talent Optimization: The company undertook restructuring efforts affecting 22 individuals across various practices and departments, incurring a $2.6 million charge. While annual cost savings are expected, there is a risk of disruption or reduced efficiency during the transition.
Credit Facility and Debt Levels: The company increased its credit facility by $50 million to support growth and working capital needs, but elevated borrowings and net debt of $159.5 million could pose financial risks if not managed effectively.
Employee-Related Costs: The first quarter is disproportionately affected by higher employee-related benefit costs and taxes due to annual bonus payments, which could strain cash flow.
Regulatory and Legal Risks: The company is involved in complex legal and regulatory projects, including antitrust and privacy class actions, which could expose it to reputational and financial risks if outcomes are unfavorable.
Market Misunderstanding of Business Model: Management expressed concerns about a fundamental misunderstanding of the company's business model in the market, which could affect investor confidence and stock performance.
Full Year Financial Guidance for Fiscal 2026: The company reaffirmed its full-year financial guidance for fiscal 2026, citing a strong start to the year, supportive market trends, and a robust sales pipeline. However, management remains cautious about potential impacts from evolving geopolitical, global macroeconomic, and business conditions.
Talent Investments and Cost Optimization: The company plans to redeploy annual cost savings of approximately $5 million from recent restructuring efforts back into the business to strengthen operations and pursue profitable growth in the coming quarters.
Credit Facility Expansion: The company increased its credit facility by $50 million, bringing the total borrowing capacity to $300 million. This expansion is intended to provide financial flexibility to support continued growth and working capital needs as annual revenues approach $800 million.
AI's Impact on Business: Management views AI as both a demand amplifier and productivity enhancer, strengthening the company's position due to its deep expertise, strong governance, and established credibility. AI is expected to enhance, but not replace, the company's expert judgment and capabilities in complex and high-stakes environments.
Dividend Payments: $3.8 million of dividend payments were made during the first quarter of 2026.
Share Repurchase: $21.5 million was spent on repurchasing approximately 116,000 shares during the first quarter of 2026.
Remaining Share Repurchase Program: $44.5 million is still available under the share repurchase program.
The earnings call reflects strong financial performance with record revenue and profitability, particularly in the Life Sciences and M&A sectors. Although there are increased costs and a restructuring charge, the company maintains a positive outlook with strong demand and utilization rates. The Q&A reveals optimism about talent acquisition and growth despite some general responses. Given the market cap, this translates to a positive stock price movement, likely between 2% to 8%.
The earnings call reveals record-high revenue and strong performance across various practices, with optimistic guidance for fiscal 2026. The Q&A section supports this with positive sentiment towards revenue growth, AI initiatives, and shareholder returns. Despite flat headcount growth, future increases are expected, aligning with revenue growth. The company's active share repurchase plan indicates confidence in undervaluation. Overall, strong financial metrics, optimistic guidance, and strategic initiatives suggest a positive stock price movement.
The earnings call summary and Q&A indicate strong financial performance, optimistic guidance, and strategic growth in key areas like energy and life sciences. The increase in dividends and share repurchases is a positive indicator for shareholder returns. Although there are concerns about headcount and long-term visibility, these are outweighed by positive growth metrics and strategic positioning. Given the market cap of $1.2 billion, the stock is likely to experience a positive movement of 2% to 8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.